Suppr超能文献

GNAQ 基因体细胞突变与无色素性/低色素性蓝色痣。

Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi.

机构信息

Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA.

出版信息

Hum Pathol. 2011 Jan;42(1):136-40. doi: 10.1016/j.humpath.2010.05.027. Epub 2010 Nov 5.

Abstract

A recent study indicates that somatic mutations in codon 209 of GNAQ, a gene encoding the signaling protein G-protein α subunit q, may be present in up to 80% of blue nevi. Given that mutations in GNAQ represent dominant dark skin (Dsk) mutations caused by increased dermal melanin, the primary aim of this study was to ascertain whether amelanotic/hypomelanotic blue nevi exhibited somatic mutations in GNAQ like their melanotic counterpart. Genomic DNA was isolated for genotyping per protocol using techniques including laser capture microdissection to isolate nevus cells from amelanotic/hypomelanotic blue nevi (n = 8). The positive control group comprised regular blue nevi (n = 10, all melanotic) and cellular blue nevi (n = 9, all melanotic), whereas the negative control group comprised other dermal-based nevomelanocytic proliferations such as intradermal melanocytic nevi (n = 9, 7 of which were amelanotic) and metastatic melanoma (n = 9, 5 of which were amelanotic). DNA sequencing analysis was performed on GNAQ spanning codon 209, BRAFV600E, NRAS1, NRAS2, and KRAS genes. Mutations in GNAQ were noted in 12.5% (1/8) of amelanotic/hypomelanotic blue nevi. In the control group 40% (4/10) of blue nevi and 44% (4/9) of cellular blue nevi demonstrated the GNAQ mutation, with no cases of metastatic melanoma or intradermal melanocytic nevi exhibiting the mutation. All GNAQ mutations were A/T point mutations, and statistically significant differences were not noted among the amelanotic/hypomelanotic blue nevi, blue nevi, and cellular blue nevi subgroups. Although additional mutations were not noted in cases of amelanotic/hypomelanotic blue nevi, one blue nevus exhibited a mutation in KRAS alone; one cellular blue nevus, a concurrent NRAS2 mutation; one cellular blue nevus, a concurrent KRAS mutation; and a third cellular blue nevus, a mutation in KRAS alone. The presence of GNAQ mutations in the amelanotic/hypomelanotic blue nevus indicates that mechanisms underlying pigment homeostasis in this variant appear to be similar to those of its melanotic counterparts, although it is not clear why activation of the q class of the G-protein α subunit should cause an abundance of dermal pigment in one variant and not in another. Given that dermal melanocytes are present since birth, one possible explanation is that their melanin-synthesizing pathway is usually in a dormant state. Activation of this pathway is a consequence of multiple triggers-one of which is a mutation in the GNAQ gene, whereas the other is yet to be identified.

摘要

最近的一项研究表明,编码信号蛋白 G 蛋白α亚单位 q 的基因 GNAQ 中的 209 密码子的体细胞突变可能存在于高达 80%的蓝色痣中。鉴于 GNAQ 中的突变代表了由于真皮黑色素增加而导致的显性暗肤色(Dsk)突变,本研究的主要目的是确定非色素性/低色素性蓝色痣是否表现出与色素性痣相同的 GNAQ 体细胞突变。根据方案使用包括激光捕获显微解剖术在内的技术分离非色素性/低色素性蓝色痣(n=8)的痣细胞,以分离基因组 DNA 进行基因分型。阳性对照组由常规蓝色痣(n=10,均为色素性)和细胞性蓝色痣(n=9,均为色素性)组成,而阴性对照组由其他真皮黑素细胞增殖组成,如真皮内黑素细胞痣(n=9,其中 7 个为非色素性)和转移性黑色素瘤(n=9,其中 5 个为非色素性)。对 GNAQ 跨越 209 密码子、BRAFV600E、NRAS1、NRAS2 和 KRAS 基因进行 DNA 测序分析。在 12.5%(1/8)的非色素性/低色素性蓝色痣中发现了 GNAQ 突变。在对照组中,40%(4/10)的蓝色痣和 44%(4/9)的细胞性蓝色痣显示出 GNAQ 突变,没有转移性黑色素瘤或真皮内黑素细胞痣出现突变。所有 GNAQ 突变均为 A/T 点突变,非色素性/低色素性蓝色痣、蓝色痣和细胞性蓝色痣亚组之间未观察到统计学显著差异。尽管在非色素性/低色素性蓝色痣中未发现其他突变,但一个蓝色痣仅显示 KRAS 突变;一个细胞性蓝色痣,同时存在 NRAS2 突变;一个细胞性蓝色痣,同时存在 KRAS 突变;第三个细胞性蓝色痣,KRAS 单独突变。非色素性/低色素性蓝色痣中存在 GNAQ 突变表明,该变异体中色素内稳态的机制似乎与其色素性对应物相似,尽管尚不清楚为什么 G 蛋白α亚单位 q 类的激活应该导致一种变体中的真皮色素大量增加,而在另一种变体中则不会。鉴于真皮黑素细胞自出生以来就存在,一种可能的解释是,它们的黑色素合成途径通常处于休眠状态。该途径的激活是多种触发因素的结果——其中之一是 GNAQ 基因的突变,而另一个因素尚待确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验